Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
16.90
-0.22 (-1.29%)
At close: Oct 28, 2025, 4:00 PM EDT
16.98
+0.08 (0.47%)
After-hours: Oct 28, 2025, 7:53 PM EDT
Adaptive Biotechnologies Stock Forecast
Stock Price Forecast
The 10 analysts that cover Adaptive Biotechnologies stock have a consensus rating of "Strong Buy" and an average price target of $15.1, which forecasts a -10.65% decrease in the stock price over the next year. The lowest target is $9.00 and the highest is $20.
Price Target: $15.1 (-10.65%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Adaptive Biotechnologies stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 4 | 5 | 5 |
| Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 8 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Maintains $14 → $19 | Strong Buy | Maintains | $14 → $19 | +12.43% | Oct 22, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $15 → $20 | Buy | Maintains | $15 → $20 | +18.34% | Oct 15, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $14 → $17 | Buy | Maintains | $14 → $17 | +0.59% | Oct 13, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +18.34% | Sep 30, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $10 → $14 | Buy | Maintains | $10 → $14 | -17.16% | Aug 6, 2025 |
Financial Forecast
Revenue This Year
240.53M
from 178.96M
Increased by 34.41%
Revenue Next Year
274.27M
from 240.53M
Increased by 14.03%
EPS This Year
-0.72
from -1.08
EPS Next Year
-0.63
from -0.72
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 268.9M | 293.6M | |||
| Avg | 240.5M | 274.3M | |||
| Low | 219.6M | 247.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 50.3% | 22.1% | |||
| Avg | 34.4% | 14.0% | |||
| Low | 22.7% | 2.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.59 | -0.58 | |||
| Avg | -0.72 | -0.63 | |||
| Low | -0.78 | -0.74 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.